140 related articles for article (PubMed ID: 17168661)
1. Farnesyltransferase inhibitors and rapamycin in the treatment of multiple myeloma.
Zangari M; Cavallo F; Tricot G
Curr Pharm Biotechnol; 2006 Dec; 7(6):449-53. PubMed ID: 17168661
[TBL] [Abstract][Full Text] [Related]
2. Targeting signaling pathways in multiple myeloma.
Federica C; Antonio P; Guido T; Mario B
Curr Pharm Biotechnol; 2006 Dec; 7(6):407-13. PubMed ID: 17168656
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma.
Santucci R; Mackley PA; Sebti S; Alsina M
Cancer Control; 2003; 10(5):384-7. PubMed ID: 14581893
[TBL] [Abstract][Full Text] [Related]
4. Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma.
Eichner R; Fernández-Sáiz V; Targosz BS; Bassermann F
Int Rev Cell Mol Biol; 2019; 343():219-297. PubMed ID: 30712673
[TBL] [Abstract][Full Text] [Related]
5. The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma.
Wang L; Lin N; Li Y
Oncol Rep; 2019 Mar; 41(3):1678-1690. PubMed ID: 30664164
[TBL] [Abstract][Full Text] [Related]
6. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
[TBL] [Abstract][Full Text] [Related]
7. The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.
Pei XY; Dai Y; Rahmani M; Li W; Dent P; Grant S
Clin Cancer Res; 2005 Jun; 11(12):4589-600. PubMed ID: 15958645
[TBL] [Abstract][Full Text] [Related]
8. Farnesyltransferase inihibitors in hematologic malignancies.
Harousseau JL
Blood Rev; 2007 Jul; 21(4):173-82. PubMed ID: 17293017
[TBL] [Abstract][Full Text] [Related]
9. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.
Gotlib J
Curr Hematol Rep; 2005 Jan; 4(1):77-84. PubMed ID: 15610664
[TBL] [Abstract][Full Text] [Related]
10. Signaling Pathways and Emerging Therapies in Multiple Myeloma.
Ramakrishnan V; D'Souza A
Curr Hematol Malig Rep; 2016 Apr; 11(2):156-64. PubMed ID: 26922744
[TBL] [Abstract][Full Text] [Related]
11. Role of farnesyltransferase inhibitors in hematologic malignancies.
Santos ES; Rosenblatt JD; Goodman M
Expert Rev Anticancer Ther; 2004 Oct; 4(5):843-56. PubMed ID: 15485318
[TBL] [Abstract][Full Text] [Related]
12. Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy.
Klochkov SG; Neganova ME; Yarla NS; Parvathaneni M; Sharma B; Tarasov VV; Barreto G; Bachurin SO; Ashraf GM; Aliev G
Semin Cancer Biol; 2019 Jun; 56():128-134. PubMed ID: 29100957
[TBL] [Abstract][Full Text] [Related]
13. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
Podar K; Richardson PG; Chauhan D; Anderson KC
Expert Rev Anticancer Ther; 2007 Apr; 7(4):551-66. PubMed ID: 17428175
[TBL] [Abstract][Full Text] [Related]
14. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma.
Harvey RD; Lonial S
Future Oncol; 2007 Dec; 3(6):639-47. PubMed ID: 18041916
[TBL] [Abstract][Full Text] [Related]
15. Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments.
Hu J; Hu WX
Cancer Lett; 2018 Feb; 414():214-221. PubMed ID: 29174802
[TBL] [Abstract][Full Text] [Related]
16. Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis.
Moorthy NS; Sousa SF; Ramos MJ; Fernandes PA
Curr Med Chem; 2013; 20(38):4888-923. PubMed ID: 24059235
[TBL] [Abstract][Full Text] [Related]
17. Farnesyltransferase inhibitors.
Kurzrock R
Clin Adv Hematol Oncol; 2005 Mar; 3(3):161-2. PubMed ID: 16166986
[No Abstract] [Full Text] [Related]
18. Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.
Karp JE; Lancet JE
Future Oncol; 2005 Dec; 1(6):719-31. PubMed ID: 16556050
[TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase inhibitors target multiple endothelial cell functions in angiogenesis.
Scott AN; Hetheridge C; Reynolds AR; Nayak V; Hodivala-Dilke K; Mellor H
Angiogenesis; 2008; 11(4):337-46. PubMed ID: 18758974
[TBL] [Abstract][Full Text] [Related]
20. Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.
Anreddy N; Hazlehurst LA
J Cell Biochem; 2017 Jan; 118(1):15-25. PubMed ID: 27261328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
